Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Tadashi Kurimoto"'
Autor:
Yukari Sato, Tokuro Shimura, Shigeyoshi Honma, Takao Tanaka, Makoto Yoshida, Tadashi Kurimoto, Satoko Ohkubo, Norimichi Nakahata
Publikováno v:
Pharmacology. 79:50-56
The effect of a novel thromboxane A2 receptor (TP) antagonist, (±)-sodium[2-(4-chlorophenylsulfonylaminomethyl)- indan-5-yl]acetate monohydrate (Z-335), on the U46619-induced responses was compared between rabbit platelets and aorta. Z-335 inhibited
Autor:
Takashi Ohashi, Takao Masuda, Tamako Ikeda, Mineo Takei, Yutaka Emori, Tadashi Kurimoto, Mari Kannagi
Publikováno v:
Journal of General Virology. 85:2603-2613
Z-100 is an arabinomannan extracted fromMycobacterium tuberculosisthat has various immunomodulatory activities, such as the induction of interleukin 12, interferon gamma (IFN-γ) andβ-chemokines. The effects of Z-100 on human immunodeficiency virus
Autor:
Keiko Yonezawa, Tohru Sugimoto, Shigeru Furuta, Takeshi Omata, Tadashi Kurimoto, Yoshihiro Kawabata, Xiaochun Cheryl Wu, Emiko Kamada
Publikováno v:
European Journal of Pharmacology. 497:223-231
In the present study, the inhibitory properties of N-[2-(diisopropylamino)ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-1,3-thiazole-4-carboxamide monohydrochloride trihydrate (Z-338), a novel gastroprokinetic agent, were investigated and compared
Autor:
Shigeru Furuta, Mineo Takei, Emiko Kamada, Yoshihiro Kawabata, Kazuho Okudaira, Ryuichiro Nishigaki, Tadashi Kurimoto
Publikováno v:
Pharmaceutical Research. 21:467-475
The characteristics of bile canalicular transport processes for xenobiotic taurine conjugates have not yet been clarified. To elucidate the biliary excretion characteristics of xenobiotic taurine conjugates, we investigated the transport of a novel t
Autor:
Akio Hiyama, Atsuhiro Inaba, Nobuhiko Kowata, Emiko Kamada, Shigeru Furuta, Michael Hall, Nobuyoshi Akagawa, Anne Matthews, Yoshihiro Kawabata, Tadashi Kurimoto
Publikováno v:
British Journal of Clinical Pharmacology. 54:295-303
Aims To identify the cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) isoforms responsible for the formation of the primary metabolite(s) of zaltoprofen, and to predict possible drug interactions by investigating the inhibition of CYP isof
Autor:
Hideaki oka, Koji Yoshinaga, Yumiko Shiraishi, Hidetaka Sasaki, Yutaka Emori, Tadashi Kurimoto
Publikováno v:
Microbiology and Immunology. 46:343-351
In the present study, the anti-tumor mechanism of Z-100 was investigated with the use of pulmonary metastasis of B16F10 melanoma. In B16F10 mice, Th1 cytokine production (IL-2, IFN-gamma) was suppressed in comparison with normal mice. On the other ha
Publikováno v:
Drug Metabolism and Disposition. 30:498-504
To elucidate the transport system by which [2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate (Z-335) is taken up into the liver, we investigated the uptake characteristics of Z-335 in isolated rat hepatocytes. In addition, we estimated the hep
Autor:
Yoshihisa Fukuta, Youich Fukuda, Tohru Sugimoto, Shigeru Furuta, Mineo Takei, Hiroshi Sano, Haruka Miyahara, Tadashi Kurimoto, Emiko Kamada
Publikováno v:
European Journal of Pharmacology. 426:105-111
The pharmacodynamics of (S)-4-[3-[4-[1-(4-methylphenyl)-3-[4-(2-methoxyphenyl)piperazine-1-yl]propoxy]benzoyl]indole-1-yl] butyric acid hydrochloride (Z-350), which has alpha(1)-adrenoceptor antagonistic and steroid 5alpha-reductase inhibitory effect
Autor:
Youichi Fukuda, Mineo Takei, Masayuki Ogishima, Tadashi Kurimoto, Yoshihisa Fukuta, Kenji Yoshida, Raita Higashino
Publikováno v:
Japanese Journal of Pharmacology. 86:323-328
We examined the hormonal effects of Z-350, (S)-4-[3-(4-{1-(4-methylphenyl)-3-[4-(2-meth-oxyphenyl)piperazine-1-yl]propoxy|benzoyl)indole-1-yl]butyric acid hydrochloride, which has both α1-adrenoceptor blocking activity and steroid 5α -reductase inh
Publikováno v:
European Journal of Pharmacology. 401:413-418
We examined the antithrombotic effect of Z-335 ((+/-)-sodium [2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate monohydrate), an orally active thromboxane A(2) receptor (TP-receptor) antagonist that ameliorates experimental gangrene, using a ra